RecruitingNot applicableNCT03141021
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Angela Hirbe, M.D., Ph.D.Washington University School of Medicine
- Enrollment
- 1050 enrolled
- Eligibility
- All sexes
- Timeline
- 2017 – 2053
Study locations (13)
- Moffitt Cancer Center, Tampa, Florida, United States
- Johns Hopkins, Baltimore, Maryland, United States
- National Institutes of Health (NIH), Bethesda, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Lifespan, Providence, Rhode Island, United States
- University of Utah, Salt Lake City, Utah, United States
- Mount Sinai, Toronto, Ontario, Canada
- Global Gene Corporation, Mumbai, India
- Nagoya University Hospital, Nagoya, Showa Ward, Japan
- Royal National Orthopedic Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03141021 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06693284A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]University of Minnesota
- RECRUITINGPHASE2NCT04872543A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT04222413Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT03872427Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI)
See all trials for Malignant peripheral nerve sheath tumor →